UK Markets open in 1 hr 32 mins

AgeX Therapeutics, Inc. (AGE)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
0.7700-0.0079 (-1.02%)
At close: 04:00PM EST
0.7700 0.00 (0.00%)
After hours: 07:09PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.7779
Open0.8050
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's range0.7440 - 0.8200
52-week range0.5160 - 3.0600
Volume77,177
Avg. volume611,822
Market cap29.213M
Beta (5Y monthly)1.21
PE ratio (TTM)N/A
EPS (TTM)-0.2370
Earnings date29 Mar 2022 - 04 Apr 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders

    ALAMEDA, Calif., December 14, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today a research collaboration with the University of California, Irvine (UCI) to explore the therapeutic potential of exosomes and other extracellular vesicles produced by neural stem cells derived from AgeX pluripotent stem cells, with the goal of developing therapies to treat adverse neurocognitive effe

  • Business Wire

    AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

    ALAMEDA, Calif., November 30, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. ("ImStem"), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStem’s lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA. I

  • Business Wire

    AgeX Therapeutics Receives Stock Exchange Deficiency Letter

    ALAMEDA, Calif., November 23, 2021--AgeX Therapeutics , Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 17, 2021 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stock